4.7 Article

COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey

Journal

JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 21, Pages -

Publisher

MDPI
DOI: 10.3390/jcm10215125

Keywords

COVID-19; Down Syndrome; paediatrics

Funding

  1. Down Syndrome Affiliates in Action
  2. Down Syndrome Medical Interest Group-USA
  3. GiGi's Playhouse
  4. Jerome Lejeune Foundation
  5. LuMind IDSC Foundation
  6. Matthew Foundation
  7. National Down Syndrome Society
  8. National Task Group on Intellectual Disabilities and Dementia Practices
  9. HERCULES Center [NIEHS P30ES019776]
  10. Library Information Technology Services grant [UL1 TR000424]
  11. Alana USA Foundation
  12. Awakening Angels Foundation
  13. Infectious Diseases Society of America (IDSA)
  14. Centre for Genomic Regulation Severo Ochoa excellence grant
  15. CIBER of Rare Diseases
  16. DURSI [2017SGR595]
  17. Spanish Ministry of Science, Innovation and Universities (MSIU)
  18. Centro de Excelencia Severo Ochoa
  19. CERCA (GenCat)
  20. MRC [MR/S011277/1, MR/S005145/1, MR/R024901/1]
  21. Lumind IDSC
  22. LeJeune Foundation
  23. European Commission [GO-DS21-848077]
  24. National Institute for Health Research (NIHR) Biomedical Research Centre based at UCL Great Ormond Street Institute of Child Health/Great Ormond Street Hospital NHS Foundation Trust
  25. ISCIII
  26. EDER [PT17/0009/0014]
  27. AEI [CEX2018-000782-M]
  28. Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya [2017 SGR 00519]
  29. Fondo de Investigaciones Sanitario (FIS), Instituto de Salud Carlos III - Fondo Europeo de Desarrollo Regional, Union Europea, Una manera de hacer Europa [PI18/00335, PI14/01126, PI17/01019]
  30. Jerome Lejeune Foundation [1319 Cycle 2019B]
  31. National Institutes of Health (NIA) [1R01AG056850 -01A1, R21AG056974, R01AG061566]
  32. Departament de Salut de la Generalitat de Catalunya, Pla Estrategic de Recerca i Innovacio en Salut [SLT006/17/00119]
  33. Fundacio La Marato de TV3 [20141210]
  34. MRC [MR/S005145/1] Funding Source: UKRI

Ask authors/readers for more resources

Research shows that children with Down Syndrome are more likely to experience severe symptoms and complications after contracting COVID-19, emphasizing the importance of identifying their risk factors and providing appropriate protection. Compared to adults with Down Syndrome, children affected by COVID-19 have lower mortality rates, indicating the need for targeted interventions and vaccination strategies for this vulnerable population.
Adults with Down Syndrome (DS) are at higher risk for severe outcomes of coronavirus disease 2019 (COVID-19) than the general population, but evidence is required to understand the risks for children with DS, which is necessary to inform COVID-19 shielding advice and vaccination priorities. We aimed to determine the epidemiological and clinical characteristics of COVID-19 in children with DS. Using data from an international survey obtained from a range of countries and control data from the United States, we compared the prevalence of symptoms and medical complications and risk factors for severe outcomes between DS and non-DS paediatric populations with COVID-19. Hospitalised COVID-19 patients < 18 years with DS had a higher incidence of respiratory symptoms, fever, and several medical complications from COVID-19 than control patients without DS < 18 years. Older age, obesity, and epilepsy were significant risk factors for hospitalisation among paediatric COVID-19 patients with DS, and age and thyroid disorder were significant risk factors for acute respiratory distress syndrome. Mortality rates were low in all paediatric COVID-19 patients (with and without DS), contrasting with previous findings in adults with DS (who exhibit higher mortality than those without DS). Children with DS are at increased risk for more severe presentations of COVID-19. Efforts should be made to ensure the comprehensive and early detection of COVID-19 in this population and to identify children with DS who present comorbidities that pose a risk for a severe course of COVID-19. Our results emphasize the importance of vaccinating children with DS as soon as they become eligible.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available